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A B S T R A C T
Purpose
Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial,
sorafenib has become the standard of care for patients with advanced unresectable hepatocellular
carcinoma, but the relation between survival advantage and disease etiology remains unclear. To
address this, we undertook an individual patient data meta-analysis of three large prospective
randomized trials in which sorafenib was the control arm.
Methods
Of a total of 3,256 patients, 1,643 (50%) who received sorafenib were available. The primary end
point was overall survival (OS). A Bayesian hierarchical approach for individual patient data meta-
analyseswas applied using a piecewise exponential model. Results are presented in terms of hazard
ratios comparing sorafenib with alternative therapies according to hepatitis C virus (HCV) or hepatitis
B virus (HBV) status.
Results
Hazard ratios show improved OS for sorafenib in patients who are both HBV negative and HCV
positive (log [hazard ratio], 20.27; 95% CI, 20.46 to 20.06). Median unadjusted survival is 12.6
(11.15 to 13.8) months for sorafenib and 10.2 (8.88 to 12.2) months for “other” treatments in this
subgroup. There was no evidence of improvement in OS for any other patient subgroups deﬁned by
HBV and HCV. Results were consistent across all trials with heterogeneity assessed using
Cochran’s Q statistic.
Conclusion
There is consistent evidence that the effect of sorafenib on OS is dependent on patients’ hepatitis
status. There is an improved OS for patients negative for HBV and positive for HCV when treated
with sorafenib. There was no evidence of any improvement in OS attributable to sorafenib for
patients positive for HBV and negative for HCV.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most
prevalent type of primary liver cancer and the
third leading cause of cancer deaths worldwide,
with more than 500,000 people affected each
year.1,2
The development of HCC has well-established
causal links to chronic viral hepatitis types B (HBV)
and C (HCV) and the other causes of chronic liver
disease.1,2 In the absence of a rigorous surveillance
program, most patients with HCC are not suitable
for potentially curative treatments such as surgical
resection, due to the advanced stage of the disease
at presentation.3
The current standard of care for advanced
unresectable HCC (aHCC) is sorafenib. The
Sorafenib Hepatocellular Carcinoma Assessment
Randomized Protocol (SHARP) trial, which in-
volved this multikinase inhibitor, was the ﬁrst
prospective, randomized, placebo-controlled trial
to show survival beneﬁt for patients with aHCC,
although this beneﬁt was modest (median survival,
10.7 months with sorafenib v 7.9 months with
placebo).4 Similar results were subsequently re-
ported from the Asia-Paciﬁc study, although the
absolute survival ﬁgures were lower.5 The differ-
ence in these two trialsmight be related to ethnicity
or differences in underlying liver function related
to the intensity of treatment before trial entry.
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In an exploratory subgroup analysis of the SHARP trial, there
was an increased survival attributable to sorafenib in patients who
were HCV positive (median survival, 14 v 7.4 months).6 Because
sorafenib was subsequently shown to have little or no effect on
HCV viral load,7 this observation was not pursued.
Three large, two-armed, noninferiority, phase III multicenter,
randomized controlled trials (RCTs) have investigated the use of
other targeted agents, namely, brivanib,8 sunitinib,9 and linifanib,10
all including sorafenib as the control arm. An aggregate meta-
analysis11 suggested that sorafenib might be more efﬁcacious in
patients positive for HCV. Other authors12-14 have considered the
hypothesis that etiologic factors (such as HCV positivity) might be
predictive of better response to sorafenib, and discussed possible
mechanisms.
In this study, we undertook an individual patient data (IPD)
meta-analysis of phase III RCTs that used sorafenib as a control
arm, with the aim of investigating the effect of etiology, deﬁned by
patients’HBVand HCV status, on overall survival (OS). IPDmeta-
analyses have a major advantage over aggregate meta-analyses in
that they ensure consistent analytic techniques and allow for de-
tailed inspection of interaction or subgroup effects that are not
available in published evidence.15,16
METHODS
Data Collection
Data were taken from three phase III clinical trials that included
sorafenib as a control arm.8-10 IPD from the brivanib and sunitinib trials
were available in their entirety. IPD from the linifanib trial were accessed by
a remote system made available by the study sponsor, and aggregate data
were extracted from equivalent models. IPD from the brivanib and
sunitinib trials and aggregate data from the linifanib trial were combined
and included in the full meta-analysis.
Data on OS as well as previously identiﬁed key prognostic factors of
interest, including Eastern Cooperative Oncology Group (ECOG) status,
extrahepatic spread, local invasion, serum biomarker alpha-fetoprotein
(AFP), HBV status, HCV status, and treatment, were collected.
Study Quality
The protocols of each study were reviewed to assess suitability of
comparisons. Registration numbers for the brivanib,8 sunitinib,9 and
linifanib10 trials were NCT00858871, NCT006993749, and NCT01009593,
respectively. All three studies were similar in terms of their overall design,
patient groups, inclusion and exclusion criteria, methods of diagnosis, and
assessment (Appendix Table A1, online only).
Statistical Methodology
All analyses were carried out on the intention-to-treat principle,
retaining patients in their initial treatment groups irrespective of any
protocol violations. The primary outcome of interest was OS measured as
the time from random assignment until death from any cause. Survival
estimates from each study were calculated using the Kaplan-Meier method,
with median follow-up calculated using the reverse Kaplan-Meier method.17
Multivariable analyses within each study were carried out using Cox pro-
portional hazards models.
Meta-analyses on IPD were carried out using a hierarchical Bayesian
model.16,18 Data were analyzed using proportional hazards methods with
a piecewise exponential model19 used to model the baseline hazard function.
Treatment comparisons and comparisons of other patient subgroups were
evaluated using hazard ratios (HRs).
Models were ﬁtted using uninformative prior distributions taking the
form of normal distributions with a zero mean and large standard de-
viations (no. 0 to 1,000) for all log HRs and the log HRs of the piecewise
exponential model. Parameter estimates were obtained from 10,000 draws
from multiple chains after convergence had been conﬁrmed. A thin of 5
was used to account for observed auto-correlation. Results are presented in
the form of forest plots, with parameter estimates presented in terms of
posterior medians and associated 95% credibility intervals.
The aim of the analysis was to evaluate the use of sorafenib as the
standard of care against alternative therapies (“other”) within patient
etiologic subgroups. Here brivanib, sunitinib, and linifanib were analyzed
as a single “other” group, with the intention of demonstrating consistency
of results across the three sources of data and of evaluating the use of
sorafenib. The main comparisons of interest were the HRs comparing
sorafenib with other alternative therapies in each etiologic subgroup. Here,
the key efﬁcacy parameters are a hierarchical term that assumed the
treatment effect comparing sorafenib with alternative therapies is not ﬁxed
but is drawn from some distribution of treatment effects and acknowledges
that the alternative therapy differs between trials included in the meta-
analysis.
Models were constructed, adjusting for known key prognostic factors
of interest—extrahepatic spread, local invasion, ECOG status, AFP status,
HBVand HCV status—as main effects. The main question of interest was
whether the effect of treatment differs according to patient etiology. All
four levels formed by the interaction between HBV and HCV were
considered with models ﬁtted, which include HRs comparing sorafenib
with alternative therapies as nested terms within each etiology status. Here,
treatment effects were estimated for each subgroup of patients depending
on their hepatitis status. The comparisons of HRs from different sources
were evaluated using the Cochran Q statistic20 to assess for model
heterogeneity.
Sensitivity analyses were carried out that compared sorafenib against
other treatments as a two-stage meta-analysis by extracting the applicable
HRs from each trial individually and comparing them using a traditional
aggregate meta-analysis approach. Further sensitivity analyses were carried
out comparing sorafenib with other therapies without adjusting for other
key prognostic factors.
Toxicity data were assessed across trials in an aggregate fashion in
terms of the number of grade 3/4 events recorded. Comparisons be-
tween sorafenib and alternative therapies are presented in terms of the
relative risk and were compared across studies using a standard ag-
gregate meta-analytical approach. Analyses considered the total
number of grade 3/4 events across trials, with heterogeneity assessed
using the I2 statistic.
IPD models were ﬁtted using the statistical package WinBUGS with
data manipulation, production of tables and ﬁgures, and the analyses of
toxicity data all produced using the statistical package R. Remotely accessed
data from the linifanib trial were evaluated using SAS Clinical Trial Data
Transparency (version 4.5; SAS Institute, Cary, NC) system. All analyses
were carried out in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines.21
RESULTS
Patient Characteristics
Data on 3,256 patients were collected from the three phase III
clinical trials (brivanib trial, n 5 1,155 [36%]8; sunitinib trial,
n5 1,070 [32%]9; linifanib trial, n5 1,031 [32%]).10 Overall, 1,643
patients (50%) received sorafenib, 577 (18%) received brivanib,
526 (16%) received sunitinib, and 510 (16%) received linifanib.
Baseline patient characteristics are listed in Table 1. Analyses were
carried out on the 2,863 patients (88%) who had both a deﬁned
HBV and HCV status and for whom OS data were available.
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Comparing the key prognostic indicators across trials, there
was evidence of different patient distributions according to ECOG
status, vascular invasion, extrahepatic spread, and HBV status.
Generally, the patient population differed in the sunitinib trial,
with a larger proportion of patients with ECOG performance status
(PS) of 1 (45.9% v 37.7% for brivanib and 34.9% for linifanib) and
a smaller proportion of patients with extrahepatic spread (33.2% v
62.5% [brivanib] and 58.3% [linifanib]). The linifanib trial had
a notably larger proportion of patients with vascular invasion
(43.5% v 27.1% and 31.9%) and smaller proportion of patients
who are hepatitis B positive (49% v 58.6% [brivanib] and 55.7%
[sunitinib]). The proportion of patients positive for HCV was
consistent across all three trials (26.9% [brivanib], 22.6% [suni-
tinib], and 25.1% [linifanib]).
Overall Survival
Median follow-upwas 20.0 months (20.8, 22.2, and 15.9months
in the brivanib, sunitinib, and linifanib trials, respectively). Un-
adjusted OS estimates from each study are given in Figure 1. Median
(95% CI) unadjusted survival estimates were 9.67 (8.78 to 10.65),
8.45 (7.76 to 9.24), and 9.1 (8.2 to 9.92) months for the brivanib,
sunitinib, and linifanib trials, respectively.
Exploratory analyses (unpublished) of patients with aHCC
identiﬁed HBV, HCV, AFP (measured on the log scale), tumor local
invasion, extrahepatic spread, and ECOG PS as key prognostic
indicators. Figure 2 shows the main effect that each of these had on
OS in their respective studies. Local invasion, extrahepatic spread,
an ECOG PS of 1 (v 0) and an increase in log AFP levels all
signiﬁcantly increased the hazard of observing an event. There was
a trend of patients who were HBV positive all having an increased
hazard compared with patients negative for HBV, although this was
only signiﬁcant in the linifanib trial. Evaluation of Cochran’s Q
statistic showed no statistically signiﬁcant evidence of heteroge-
neity for any of the main effects (Appendix Table A2, online only).
Median (95% CI) unadjusted OS estimates were 9.44 (8.55 to
10.65), 7.92 (7.36 to 9.23), 8.97 (7.96 to 9.89), and 9.30 (8.58 to
10.52) for patients receiving brivanib, sunitinib, linifanib, and
sorafenib, respectively. Hierarchical modeling comparing sorafenib
Table 1. Patient Demographics by Trial
Variable
Study
PJohnson et al8 (N = 1,155) Cheng et al9 (N = 1,070) Cainap et al10 (N = 1,031)
Arm N/A
Sorafenib 578 (50) 544 (50.8) 521 (50.5)
Brivanib 577 (50) N/A N/A
Sunitinib N/A 526 (49.2) N/A
Linifanib N/A N/A 510 (49.5)
Sex .528
Female 188 (16.3) 179 (16.7) 155 (15.0)
Male 967 (83.7) 891 (83.3) 876 (85.0)
Age, median (IQR), years 61 (53-69) 59 (49-68) 60 (51-68) N/A
ECOG status , .001
0 720 (62.3) 577 (54.1) 671 (65.1)
1 435 (37.7) 490 (45.9) 360 (34.9)
Vascular invasion , .001
No 842 (72.9) 712 (68.1) 583 (56.5)
Yes 313 (27.1) 334 (31.9) 448 (43.5)
Extrahepatic spread , .001
No 433 (37.5) 715 (66.8) 430 (41.7)
Yes 722 (62.5) 355 (33.2) 601 (58.3)
AFP, median (IQR), ng/mL 160 (9.0 to 2,537) 256 (13 to 4,000) 389 (17.5 to 8,523) .111
HBV , .001
No 361 (41.4) 459 (44.3) 526 (51.0)
Yes 512 (58.6) 578 (55.7) 505 (49.0)
HCV .101
No 640 (73.1) 786 (77.4) 772 (74.9)
Yes 235 (26.9) 230 (22.6) 259 (25.1)
NOTE. Data given as No. (%) unless otherwise indicated.
Abbreviations: AFP, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range; N/A, not
applicable.
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Fig 1. Overall survival estimates from the brivanib,8 sunitinib,9 and linifanib10
trials.
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with all alternative therapies did not give sufﬁcient evidence of an
overall beneﬁt associated with sorafenib in terms of OS (log
HR, 20.13; 95% CI, 20.38 to 0.07).
Comparisons of sorafenib against other therapies within hepatitis
subgroups. Unadjusted Kaplan-Meier plots showing the OS for
sorafenib and other patient groups by their hepatitis status are
presented in Figure 3. Comparisons were considered for the four
levels created by the combination of HBVand HCV status, namely,
(1) HBV negative, HCV negative; (2) HBV positive, HCV negative;
(3) HBV negative, HCV positive; and (4) HBV positive, HCV
positive. The distribution of patients across these four subgroups is
listed in Table 2. Most patients were HBV positive, HCV negative
(1,474 of 2,863 patients [51%]). Median (95% CI) OS rates (in
months)were 10.42 (9.38 to 11.46), 11.41 (10.19 to 12.63), 7.76
(7.10 to 8.36), and 8.5 (6.22 to 10.78) for the four respective
scenarios.
The results of the IPD meta-analyses are given in Figure 4 and
show treatment effects comparing sorafenib with other therapies
within the four subgroups created by the interaction of HBV and
HCV. For patients negative for HBV and HCV (n 5 689), there is
some evidence of improved survival in patients who received
sorafenib, but this was not considered signiﬁcant because the 95%
CI contains zero (log HR,20.11; 95%CI,20.28 to 0.09). A similar
magnitude of effect was observed for patients who were positive for
both HBV and HCV, but with a much larger CI due to reduced
patient numbers (n5 72; log HR,20.11; 95% CI,20.45 to 0.25).
Patients positive for HCVand negative for HBV (n5 628) were the
only group to have signiﬁcant evidence that patients treated with
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Fig 2. Comparison of the effect of prognostic factors on OS from the brivanib, sunitinib, and linifanib trials. AFP, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology
Group; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; Inv, invasion; Neg, negative; OS, overall survival; Pos, positive.
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sorafenib had better OS than the comparator (log HR,20.26; 95%
CI, 20.46 to 20.04). This result is consistent across all sources of
data and there is no evidence of heterogeneity based on Cochran’s
Q statistic (Q5 2.032; P 5 .362). Patients who were HBV positive
and HCV negative comprised the largest cohort of data from the
three contributing studies (n 5 1,474). There was no evidence in
this group that there was a beneﬁcial effect on OS attributable to
sorafenib; the pooled HR slightly favored the comparator (log HR,
0.05; 95% CI, 20.10 to 0.21). Sensitivity analyses showed little
impact on the reportedHRs due tomethodology applied and did not
impact the overall interpretations of the data. Details are listed in
Appendix Table A3 (online only). Further investigations were carried
out to determine if ethnicity was a confounding factor, but this did
not have a signiﬁcant impact on the model ﬁt in any of the three
included studies (Appendix Table A4, online only). The number of
grade 3/4 adverse events by type is listed in Table A5 (online only).
DISCUSSION
We have carried out an IPD meta-analysis of three phase III RCTs
that demonstrates that the effect of sorafenib compared with other
treatments for patients with aHCC cannot be considered in-
dependent of a patient’s HBV and HCV status. For patients who
were HBV positive and HCV negative, there was no evidence of any
positive effect on OS due to sorafenib, with the HR in this subgroup
favoring the comparator, although this was not statistically signiﬁcant.
This patient group comprises 51% of all patients included in the
analysis. There was, however, a signiﬁcant positive effect of sorafenib
in the group of patients who were HCV positive and HBV negative
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Fig 3. Kaplan-Meier plots showing the effect of sorafenib against “other” therapies by hepatitis B virus (HBV) and hepatitis C virus (HCV) status. Overall survival is
presented for the following four subgroups: (A) HBV negative, HCV negative; (B) HBV positive, HCV negative; (C) HBV negative, HCV positive; (D) HBV positive, HCV
positive.
Table 2. Distribution of Patients Across Hepatitis Status
HCV
HBV
Neg Pos Total
Neg 689 1,474 2,163
Pos 628 72 700
Total 1,317 1,546 2,863
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; Neg, negative;
Pos, positive.
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(n 5 628; 22%). For all remaining patients, there was a trend sup-
porting the use of sorafenib, but this was not statistically signiﬁcant.
Our analysis extends the previous aggregate meta-analysis,
which, although lacking the ability of IPD analyses to investigate
treatment effects within patient subgroups, did involve additional
trials to ours (the SHARP4 and Asia-Paciﬁc region5 studies) and
concluded that sorafenib might provide more survival beneﬁts to
patients positive for HCV. IPD meta-analyses are the gold standard
and allow us to analyze trial data that may be more mature than the
published results, ensure consistency of analytical techniques across
the data sources, and further allow for the inspection of subgroup
effects and treatment interactions, whichwould not be possible using
an aggregate meta-analytical approach. Still, the results reported here
represent secondary analyses of trial subgroup effects and the evi-
dence provided is not as strong as a RCT, which speciﬁcally would
look at the effect of sorafenib within each hepatitis subgroup.
The subgroup analysis of the SHARP trial showed that pa-
tients positive for HCV had a superior median OS of 14 months
compared with 7.4 months in the placebo-treated group, and this
beneﬁt was also seen in terms of time to tumor progression (7.6 v
2.8 months) and disease control rate (44.2% v 29.6%).6 As noted
by Bruix et al,6 the SHARP trial was not randomized relative to
etiology and, therefore, the resulting subgroups were at risk for
imbalance. Nonetheless, inspection of the data provided in this
subgroup analysis shows that there were a signiﬁcant number of
patients within the HCV-positive subgroup (n 5 167; 86 receiving
sorafenib and 81 receiving placebo), and that the treated and the
placebo groups were, in fact, well balanced with respect to region,
age, sex, Child-Pugh class, macrovascular invasion/extrahepatic
spread, ECOG PS, and disease stage. These observations, com-
bined with the present detailed IPD meta-analysis and the previous
aggregated meta-analysis, support the contention that the impact of
sorafenib is largely conﬁned to the patients who are HCV positive.
Because the overall beneﬁt of sorafenib in the SHARP study was only
2.8 months compared with placebo, and we found little signiﬁcant
overall effect of sorafenib in the analyses presented here, there is
insufﬁcient evidence to support the absolute beneﬁt of sorafenib
outside patients positive for HCV. We considered the possibility that
ethnicity might be a confounding factor (because HCVand HBVare
more prevalent in Western and Eastern populations, respectively),
but our analysis did not support this contention. Treatment before
trial entry, which may be less intense in Western (and, hence, HCV-
positive) populations may also be a confounding factor, but we had
insufﬁcient data to exclude this possibility.
There is evidence of genetic diversity22-25 in HCC that can be
linked to speciﬁc etiologic factors22,26 and may permit identiﬁ-
cation of speciﬁc targets for therapy. The reasons for differential
response to sorafenib according to etiology remain unclear. Al-
though some in vitro data have suggested that sorafenib inhibits
HCV viral replication directly, this has not been borne out in the
clinical setting.7,27 There is evidence ofWnt-pathway dysregulation
in about 50% of HCC cases. Of the two major activating classes
(CTNNB1 and Wnt-TGFb), the former appears to be related
to HCV infection and activity is modulated by sorafenib in a xe-
nograft model.13,24,28 HCV has also been shown to upregulate
C-RAF,29 a known sorafenib target, and Braconi et al30 have shown
that HCV proteins can modulate the expression of microRNAs and
thereby inﬂuence the sensitivity of HCC cells to sorafenib.
Irrespective of the mechanism, our data suggest that in future
trials in aHCC, particularly where sorafenib is the control arm,
there should be stratiﬁcation according to etiology. Etiologic
differences have already been considered as factors in the in-
terpretation of clinical trials. In the trial of adjuvant sorafenib after
surgical resection or local ablation (STORM), although the overall
results of the trial were negative, there was a trend for longer time
to recurrence in the HCV-related cases.31
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Fig 4. Forest plots showing the effect of sorafenib against “other” therapies by the four subgroups created by HBV and HCV subgroups. HBV, hepatitis B virus; HCV,
hepatitis C virus; HR, hazard ratio; OS, overall survival.
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Following a proposal from the International Committee of
Medical Journal Editors32, it is likely that individual patient data will
become accessible to investigators unrelated to the original trial. Thus,
as a condition of consideration for publication, it is proposed that
authors will be required to include a description of the data-sharing
plan in the submitted manuscript. Although the editors considered
that “sharing datawill increase conﬁdence and trust in the conclusions
drawn from clinical trials,”32(p468) our study shows how the beneﬁts of
access to completed trial data are not necessarily conﬁned to reanalysis
of the original hypothesis tested by the trial. Here, by a meta-analysis,
we arrive at an answer to a question that was not considered when the
trials were conceived and could not have been answered by any of the
trials individually. It also illustrates the clinical beneﬁt arising when
enlightened pharmaceutical companies are prepared to share their
data with an academic unit, even when the primary question does not
relate to their products.
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Appendix
Supplementary Material
Assessment of liver function in clinical trial protocols for targeted treatment of hepatocellular carcinoma (4 papers):
• Trial A: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial9
• Trial B: Brivanib versus sorafenib as ﬁrst-line therapy in patients with unresectable, advanced hepatocellular carcinoma:
Results from the randomized phase III BRISK-FL study8
• Trial C: Sorafenib in advanced hepatocellular carcinoma4
• Trial D: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III
trial10
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Table A1. Trials A to D
Study Characteristic
Trials*
A B C D
Liver function: inclusion criteria
Albumin, g/dL — $ 2.8 $ 2.8 $ 2.8
ALT concentration # 5 times ULN # 5 times ULN # 5 times ULN # 5 times ULN
AST concentration # 5 times ULN # 5 times ULN # 5 times ULN # 5 times ULN
Bilirubin concentration, mg/dL # 2 (or # 3 with
albumin . 3.5 g/dL)
# 3 # 3 # 3
Child-Pugh class A A A A
Liver function: exclusion criteria
Ascites Clinically relevant Any — Moderate
Encephalopathy — Any — . grade 2 per National
Cancer Institute
Varices Bleeding within
12 months
Bleeding within
2 months
— —
Bone marrow function: inclusion
criteria
Coagulation (INR) — # 2.3 (or PT # 6 s
longer than control)
# 2.3 (# 6 s longer
than control)
PT # 6 seconds prolonged
Hemoglobin, g/dL — $ 8.5 $ 8.5 —
Neutrophils (absolute), per mL $ 1,500 $ 1,500 — —
Platelets $ 75,000/mL $ 60 3 109/L $ 60 3 109/L $ 75 3 109/L or $ 50 3 109/L
(if splenomegaly)
Other inclusion criteria
Serum creatinine — # 2.0 mg/dL # 1.5 times ULN # 1.5 times ULN
Lipase — # 1.5 times ULN — —
Amylase — # 1.5 times ULN — —
Serum creatinine — # 2.0 mg/dL # 1.5 times ULN # 1.5 times ULN
Previous TACE Yes Yes Yes Yes, if . 6 months of
initiating drug treatment
in trial
ECOG PS # 1 # 1 # 2 # 1
Diagnostic conﬁrmation
Cytologic — Yes — Yes
Histologic Yes Yes — Yes
Staging system
BCLC Yes, retrospectively Yes, retrospectively Yes, retrospectively —
CLIP Yes, retrospectively — — —
Stratiﬁcation
ECOG PS — Yes Yes Yes
Geographical region Yes — Yes Yes
Prior TACE Yes — — —
Site Yes — —
Tumor invasion
(extrahepatic+/vascular
invasion)
Yes Yes Yes Yes
HBV — — — Yes
ECOG PS — Yes Yes Yes
Abbreviations: —, unspeciﬁed or ambiguous data; BCLC, Barcelona Clinic Liver Cancer (Group); CLIP, Cancer of the Liver Italian Program; ECOG PS, Eastern Co-
operative Oncology Group performance status; HBV, hepatitis B virus; INR, international normalized ratio; PT, prothrombin time; TACE, transcatheter arterial che-
moembolization; ULN, upper limit of normal.
*Overall, in terms of inclusion and exclusion criteria, diagnostic conﬁrmation of hepatocellular carcinoma, and stratiﬁcation, trials A through D were largely similar.
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Table A2. Cochran’s Q Statistic for the Consistency of Treatment Effects
Factor Q P
Main Effects
AFP 0.27 .75
ECOG 5.21 .058
Invasion 3.77 .152
Spread 1.07 .58
HBV 0.88 .643
HCV 2.68 .261
Treatment effects
HBV: Neg, HCV: Neg 0.06 .97
HBV: Neg, HCV: Pos 0.12 .94
HBV: Pos, HCV: Neg 2.03 .362
HBV: Pos, HCV: Pos 0.73 .692
Abbreviations: AFP, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology
Group; HBV, hepatitis B virus; HCV, hepatitis C virus; Neg, negative; Pos,
positive.
Table A3. Results of Sensitivity Analyses on Primary Outcome Measures
Scenario
Primary Analysis
(95% CI)
Two-Stage Meta-Analysis
(95% CI)
Unadjusted Meta-Analysis
(95% CI)
HBV2; HCV2 20.11 (20.28 to 0.09) 20.09 (20.27 to 0.09) 20.15 (20.34 to 0.04)
HBV2; HCV+ 20.26 (20.46 to 20.04) 20.25 (0.45 to 20.07) 20.25 (20.51 to 20.05)
HBV+; HCV2 0.05 (20.10 to 0.21) 0.01 (20.10 to 0.13) 0.06 (20.08 to 0.22)
HBV+; HCV+ 20.11 (20.45 to 0.25) 20.16 (20.52 to 0.20) 20.13 (20.44 to 0.19)
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus.
Table A4. The Impact of Patient Ethnicity on Etiology as a Predictive Marker
Study No. of Patients European No. of Patients Asian
Johnson et al8 (sorafenib v brivanib)
HBV2; HCV2 103 20.255 (0.243) 45 20.239 (0.364)
HBV2; HCV+ 80 20.761 (0.31) 114 20.2 (0.222)
HBV+; HCV2 36 0.053 (0.415) 450 0.067 (0.107)
HBV +; HCV+ 10 20.197 (0.534) 6 0.349 (0.418)
Cheng et al9 (sorafenib v sunitinib)
HBV2; HCV2 112 20.235 (0.236) 138 0.166 (0.193)
HBV2; HCV+ 64 20.521 (0.347) 131 20.257 (0.211)
HBV+; HCV2 21 20.03 (0.519) 503 20.111 (0.1)
HBV+; HCV+ 6 0.424 (0.79) 16 20.438 (0.308)
Cainap et al10 (sorafenib v linifanib)
HBV2; HCV2 165 20.021 (0.076) 129 0.009 (0.221)
HBV2; HCV+ 117 20.185 (0.249) 103 20.220 (0.248)
HBV+; HCV2 31 0.542 (0.724) 435 0.117 (0.114)
HBV+; HCV+ 4 N/A 29 0.574 (0.517)
NOTE. In each study, separate models that include local hepatic spread, ECOG status, local invasion, and log AFP values were included as well as the effect of sorafenib
in the four etiologic subgroups created by the interaction of HBV andHCV. Appendix Table A5 lists the number of patients in each subgroup aswell as the log hazard ratios
in the four etiologic subgroups of interest. In none of the studies did the inclusion of ethnicity, either with or instead of etiologic status, improve the model ﬁt in terms of
the observed AIC. The results show there are obvious differences in the etiologic status of European and Asian populations, with patients negative for both HBV and HCV
being more prevalent in European populations and patients positive for HBV and negative for HCV being more prevalent in Asian populations. Comparing the effect of
sorafenib with alternative therapies, the effects were reasonably consistent across the three trials. For the main subgroup of interest (ie, HBV negative; HCV positive),
there is some evidence in the brivanib and sunitinib trials that there were increased effects due to sorafenib in the European populations (log HR, 20.761 and 20.521
observed, respectively); however, these occurred in relatively small subgroups and were not repeated in the linifanib study.
Abbreviations: AFP, alpha-fetoprotein; AIC, Akaike information criterion; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus;
N/A, not applicable.
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Table A5. Summary of Toxicity by Trial
Adverse Event
Cheng et al9 Johnson et al8 Cainap et al10
Sunitinib
(n = 526)
Sorafenib
(n = 542)
Brivanib
(n = 575)
Sorafenib
(n = 575)
Linifanib
(n = 510)
Sorafenib
(n = 519)
N % N % N % N % N % N %
Overall 432 82.1 402 74.2 387 67.3 375 65.2 435 85.3 389 75
Thrombocytopenia 156 29.7 25 4.6 — — — — 27 5.3 11 2.1
Diarrhea 38 7.2 49 9 36 6.3 40 7 61 12 48 9.2
Decreased appetite 30 5.7 20 3.7 48 8.3 17 3 22 4.3 13 2.5
Hand-foot syndrome 70 13.3 114 21.1 12 2 86 15 70 13.7 77 14.8
Neutropenia 135 25.7 12 2.2 — — — — 20 3.9 12 2.3
Anemia 49 9.3 22 4 — — — — 15 2.9 28 5.4
Fatigue 33 6.3 21 3.9 84 14.5 38 7 49 9.6 25 4.8
Leukopenia 69 13.2 5 0.2 — — — — 18 3.5 12 2.3
Nausea 6 1.1 5 0.9 12 2 2 0.3 — — — —
Abdominal pain 20 3.8 14 2.6 40 7 31 5.3 — — — —
Pyrexia 3 0.6 3 0.6 3 0.5 2 0.3 — — — —
Hypertension 20 3.8 15 2.8 77 13.3 31 5.3 106 20.8 45 10.6
Rash 4 0.8 18 3.3 6 1 12 2 — — — —
Vomiting 14 2.7 7 1.3 17 3 3 0.5 22 4.3 4 0.8
Abdominal distention 12 2.3 7 1.3 23 4.5 14 2.7
Constipation 2 0.4 1 0.2 2 0.3 1 0.2 — — — —
Stomatitis 8 1.5 2 0.4 — — — — — — — —
Ascites 27 5.2 18 3.3 — — — — 31 6.1 17 3.3
AST level increased 46 8.8 49 9 87 15 98 17 62 12.2 65 12.5
Asthenia 34 6.5 24 4.4 36 7.1 11 2.1
Weight decreased 5 1 8 1.5 23 4 12 2 — — — —
Alopecia 0 0 1 0.2 — — — —
Hyponatremia — — — — 133 23 53 9.2 19 3.7 17 3.3
ALT level increased — — — — 42 7.3 46 8 11 2.2 25 4.8
Headache — — — — 6 1 2 0.3
Hyperbilirubinemia — — — — 69 12 52 9 32 6.3 21 4
Dizziness — — — — 6 1 2 0.3 — — — —
Hepatic encephalopathy — — — — — — — — 37 7.3 17 3.3
Hypokalemia — — — — — — — — 24 4.7 12 2.3
Platelet count decreased — — — — — — — — 17 3.3 10 1.9
Hypoglycemia — — — — — — — — 16 3.1 4 0.8
Blood bilirubin level increased — — — — — — — — 23 4.5 18 3.5
Abbreviation: —, no data.
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